TD Cowen Raises Target Price for Guardant Health

Summary

TD Cowen raised the price target for Guardant Health (NASDAQ:GH) from $63.00 to $72.00, maintaining a ‘buy’ rating. This suggests an 18.73% upside from the previous close. Other analysts have also increased their targets, with Scotiabank setting it at $60.00 and Guggenheim at $67.00. Guardant Health’s stock traded at $60.64, with a market cap of $7.56 billion. The company reported a revenue increase of 31% year-over-year, with an EPS of ($0.44) for the last quarter, surpassing estimates. Insiders have sold shares recently, reducing their ownership stakes.Market Beat

Impact Analysis

So basically, TD Cowen’s price target hike to $72.00 for Guardant Health is a strong vote of confidence, especially given the 31% year-over-year revenue increase and EPS beat last quarter Market Beat. The interesting part isn’t just the target hike itself, but the broader analyst consensus moving upwards, with targets ranging from $60 to $75 Market Beat+ 2. This suggests a robust belief in Guardant’s growth trajectory despite recent insider selling and a slight dip in stock price Tip Ranks+ 2. The market might be underestimating the positive sentiment from institutional investors, who hold a significant 92.60% stake Market Beat. I’d read this as a strong buy signal, particularly if the company can continue to exceed revenue expectations and address any concerns around insider selling. Watch for any further analyst upgrades or significant insider activity as potential catalysts.